AKT1 and breast carcinoma: The observed changes in phospholipid and glucose metabolism are congruent with the previous reports examining the effect of the AKT inhibitors perifosine and MK-2206 on breast cancer cells,27,29 and suggest that choline-containing metabolites and lactate may serve as non-invasive metabolic biomarkers for monitoring the effects of AKT inhibitors.